![Gregory Conn](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Förmögenhet: 108 882 $ per 2026-06-30
Gregory L.
Conn is the founder of PDS Operating Corp.
Dr. Conn is Chief Scientific Officer at PDS Biotechnology Corp.
since 2005.
Dr. Conn was Director of the Process Development Department at Covance Biotechnology Services, Inc. from 1998 to 2000.
Dr. Conn completed graduate and doctorate degrees at Albert Einstein College of Medicine, Inc.
| Företag | Datum | Antal aktier | Värdering | Värderingsdatum |
|---|---|---|---|---|
PDS BIOTECHNOLOGY CORP. 0,22 % | 2026-01-12 | 123 589 ( 0,22 % ) | 108 882 $ | 2026-06-30 |
| Företag | Position | Start |
|---|---|---|
| PDS BIOTECHNOLOGY CORPORATION | Teknisk/Vetenskaplig/F&U Direktör | 2005-01-01 |
| Företag | Position | Slut |
|---|---|---|
Covance Biotechnology Services, Inc.
 Covance Biotechnology Services, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Företagsledare/Principal | 2000-01-01 |
PDS Operating Corp.
 PDS Operating Corp. Pharmaceuticals: MajorHealth Technology Develops novel cancer immunotherapies and vaccines for infectious disease | Grundare | - |
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Första gradens relationer
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
| Privata företag | 4 |
|---|---|
PDS Operating Corp.
PDS Operating Corp. Pharmaceuticals: MajorHealth Technology Develops novel cancer immunotherapies and vaccines for infectious disease | Health Technology |
Covance Biotechnology Services, Inc.
Covance Biotechnology Services, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Health Technology |
Albert Einstein College of Medicine, Inc.
 Albert Einstein College of Medicine, Inc. Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
PDS Biotechnology Corp.
 PDS Biotechnology Corp. Pharmaceuticals: MajorHealth Technology Develops clinical-stage immunotherapies to treat various early-stage and late-stage cancers which includes head & neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer and related cancers | Health Technology |
Välj din utgåva
All finansiell information anpassad till den nationella nivån
